CORNEAL AND OCULAR SURFACE IMMUNOLOGY AND REGENERATION
Associate Professor Holly Chinnery,
Inaugural Ian Constable Research Fellow,
Lions Eye Institute,
UWA Optometry at The University of Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | November 2024
Associate Professor Holly Chinnery is a teaching and research academic in the field of corneal and ocular immunology who has spent her career teaching anatomy and immunology to Optometry students at the University of Melbourne and now at UWA, while also leading a Corneal and Ocular Immunology Research team.
Career highlights include:
– Leading a team of students and early career staff over the past 15 years working on corneal and retinal immunology, a co-leading the FrontTear Research Centre with Professor Laura Downie at the University of Melbourne https://www.fronttear.au/
– Receiving NH&MRC Ideas and ARC Discovery Grant funding
– Speaking invitations at Oxford University, University of Birmingham and the Association for Research in Vision and Ophthalmology; and recent publications in PNAS and Nature Reviews Immunology.
Assoc Professor Chinnery’s career in ocular immunology began with a focus on animal models; however, it has recently transitioned into clinical imaging studies involving human research participants. The ability to visualise the immune system and sensory nerves in the human cornea represents a significant advantage in corneal immunology and neuroimmunology research.
This advancement is made possible through a methodology called Functional In Vivo Confocal Microscopy (Fun-IVCM), which enables the observation of immune cell dynamics in the living human eye. Utilising this technology led to a breakthrough in the field of ocular immunology, culminating in a report published in PNAS, a highly prestigious journal, regarding the presence of T cells in the healthy human cornea https://www.pnas.org/doi/full/10.1073/pnas.2217795120.
This finding challenges existing dogmas and is poised to reshape the field of corneal immunology, prompting a reconsideration of previously held beliefs about how the cornea manages inflammation and immune protection, with direct implications for healthy vision.
For the first time, a variety of immune cells can be visualised in the living human cornea, generating a wealth of new questions about immunology, cell biology, and the effects that diseases outside the eye have on immune cells at the eye’s surface.
In her recent appointment at the Lions Eye Institute, Assoc Professor Chinnery aims to establish and support a team of researchers focused on corneal and ocular surface regeneration, which is one of the key research priorities of the Institute.
-
Biopsychosocial approaches to obsessive-compulsive, body image and eating disorders
Dr Nicola Acevedo is a Neuroscientist and Research Fellow with extensive expertise in developing novel therapeutics for neurological and psychiatric disorders, contributing to more than ten clinical trials. She specialises in brain stimulation and psychedelic treatments for obsessive-compulsive disorder (OCD) and related conditions, with a strong commitment to advancing personalised, evidence-based neurobiological therapies for severe psychiatric illness. Her approach integrates biopsychosocial and person-centred principles to improve treatment access and mental health outcomes.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Novel therapy for pancreatic cancers, targeting molecular foundation
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
